Engineering the Next Era of Intelligent Immunotherapy with Pioneera Biosciences
Redefining Cell and Gene Therapy Through AI-Powered Modular Platforms
Anastasija Hadunkina and Clemente Francavilla

Redesigning CAR-T & CAR-NK Therapy With Modular AI-Powered Platforms
With the global surge in cancer and autoimmune disorders, the need for smarter, scalable, and more accessible therapies is critical. Pioneera Biosciences, founded in Lithuania, is meeting this demand head-on through Discovery 4.0™, the world’s first AI-powered modular engineering engine for cell therapies.
Pioneera is transforming the immunotherapy landscape by radically accelerating the design and development of CAR-T and CAR-NK therapies. Discovery 4.0™ enables researchers to identify optimal targets, simulate tumor microenvironments in 3D, and design bispecific constructs, all within a unified, scalable framework.
Built on AI, reinforced by modular biotechnology, and designed for adaptability, Pioneera’s platform is redefining how precision immune therapies are engineered and delivered, from bench to bedside.
How It Works
Pioneera’s Discovery 4.0™ platform integrates:
- Transformer-based AI models for rapid biomarker mapping
- Reinforcement learning to optimize CAR constructs
- Tunable modular CARs for solid and hematologic tumors
- Delivery tools compatible with mRNA-LNP, lentiviral vectors, and electroporation
This novel approach not only accelerates IND timelines but also reduces cost-of-goods (COGS), tackles immune evasion, and makes allogeneic therapies scalable for real-world clinical adoption.
Why Is This Problem Significant, & How Large Is Its Impact?
The global cell and gene therapy market is projected to exceed $76 billion by 2030. Yet many current solutions are siloed, costly, or ineffective against solid tumors. Pioneera’s platform addresses this with a flexible, AI-native approach built for rapid iteration and broad application, from cancer to autoimmunity and infectious diseases.
With therapies already advancing toward Phase 1/2 clinical trials, Pioneera is positioned at the intersection of technology, biology, and translational medicine.
Meet the Team Behind Pioneera
Pioneera is powered by a cross-functional team of award-winning scientists, tech leaders, and regulatory experts:
- Dr. Alireza Daneshvar, CEO – PharmD, MPH, Forbes 30 Under 30, Chemistry Olympiad Gold Medalist, ex-Founder in Residence at Entrepreneur First. A biopharma scientist pioneering scalable immunotherapy.
- Dr. Mohammad H. Sharifnia, CIO – IFIA Elite Member and PhD candidate in Biomedical Engineering at UC Davis, spearheading AI-powered modular CAR design.
- Dr. Rakhshan Mashayekhi, CSO – An expert in drug delivery and pharmaceutical technologies with hands-on experience in biotech scale-up and scientific operations.

CEO
“We're not just building therapies — we’re building an intelligent and precise infrastructure for the future of immunotherapy. Born in Lithuania, and powered by global science, with strategic moves within the UAE and MENA region, Discovery 4.0™ is our blueprint for transforming care delivery and accessibility in oncology and beyond.”
Why We’re Excited to Invest
Pioneera represents exactly what global biotech innovation needs today — agile, regionally rooted, and globally scalable.
With patented technologies, clinical collaborations already underway (with world-class institutions), and institutional endorsements from the Department of Health Abu Dhabi, Pioneera has already outperformed its early-stage benchmarks.
The team has secured pilot discussions with international partners, joined global accelerators like Plug and Play and Nucleate, and won recognition from Abu Dhabi Global Health Week Innovation Awards, MedTech World, Forbes, and Startup Lithuania. Backed by an expert advisory board from Harvard, UCL, and Microsoft, Pioneera is a rare combination of scientific excellence and commercial readiness.
As Gulf countries scale their biotech ecosystems and Europe doubles down on advanced therapeutics, Pioneera is poised to become a continental and regional leader in immunotherapy design and delivery.
Plug and Play is one of the most active VCs in Silicon Valley. Our goal is to fund the teams building the defensible businesses of the future. Join our ecosystem today.





